The short-term outcomes of pharmaco-invasive reperfusion strategy in STEMI depending on the choice of thrombolytic drug
Background: results of the use of various thrombolytic drugs in pharmaco-invasive reperfusion are limited. Objective: to evaluate the short-term (hospital) results of the pharmaco-invasive reperfusion strategy for acute myocardial infarction with ST-segment elevation (STEMI), depending on the choice of thrombolytic drug. Materials and methods: the analysis of the results of treatment of 240 patients was carried out, which were divided into 4 groups depending on the choice of the thrombolytic drug (Actylise, Metalise, Fortelysine, Streptokinase). Results. Pharmaco-invasive reperfusion with drugs Actylise, Metalise, Fortelysine, Streptokinase is characterized with comparable rates of major adverse cardiovascular events and bleeding at the hospital stage. There are better laboratory and instrumental outcomes when using fibrin-selective drugs in comparison with streptokinase. In the hospital period, fibrin-selective drugs are characterized with comparable laboratory-instrumental indicators against a significantly lower level of troponin Т after thrombolysis with the use of Fortelysine compared with Actylise. Conclusions: fibrin-selective thrombolytic drugs determine better results of pharmaco-invasive reperfusion at the hospital stage.